EYLEA® (aflibercept) 8 mg
Neovascular (wet) age-related macular degeneration (nAMD)
CONFIDENCE IN YOUR CHOICE WITH EYLEA® (aflibercept) 8 mg
Give your eligible
- Mean CRT reductions in the EYLEA 8 mg 8q12 and 8q16 arms (PULSAR) were −123.1 µm and −128.0 µm 4 weeks after 1 dose and reduction was maintained through Weeks 96–156.
EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).
- Lasting vision gains through Week 156
- As few as 10 injections over 3 years
- Superior fluid resolution by Week 16 vs EYLEA 2 mg
- Earlier fluid‑free status vs EYLEA 2 mg (post‑hoc analysis)*
- Sustained drying through Week 156
- ~1 in 4 patients last assigned to Q24 at Week 156
- Patients with stable visual and/or anatomic outcomes can maintain or extend previous treatment intervals after the first injection of EYLEA 8 mg†
- Patients with suboptimal visual and/or anatomic outcomes may start with 1 injection per month of EYLEA 8 mg for up to 3 consecutive doses‡
*Median time to fluid-free central subfield is from a PULSAR post hoc analysis and results should be interpreted with this limitation in mind.
†Stable patients switching to EYLEA 8 mg do not require loading doses and can maintain or extend previous treatment intervals after the first injection of EYLEA. For patients who have previously been treated with EYLEA 2 mg or other anti-VEGF medicinal products and are switching to EYLEA 8 mg, the treatment regimen can differ from that used for treatment-naïve patients. Treatment intervals should be determined based on visual and/or anatomic outcomes: in patients with stable visual and/or anatomic outcomes, previous treatment intervals can be maintained or extended after the first injection of EYLEA 114.3 mg/mL, such as with a T&E dosing regimen; in patients with suboptimal visual and/or anatomic outcomes, treatment with EYLEA 8 mg may begin with 1 injection per month for up to 3 consecutive doses followed by adjustment of injection intervals, such as with a T&E dosing regimen. Consult the SmPC for full posology.
‡Following 3-monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to 6 months (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable.
PULSAR
Optimise vision whilst minimising burden
In PULSAR, lasting BCVA gains from baseline were non-inferior with EYLEA 8 mg vs EYLEA 2 mg and maintained through Week 156, with as few as 10 injections over 3 years*
*Includes 3 initial monthly doses.
†eFAS, observed cases.
Extend treatment intervals for eligible patients in your nAMD clinic
At Week 156, >8 in 10 patients in the EYLEA 2Q8→8 mg group achieved a last completed dosing interval of ≥Q12 at Week 156, within a year of switching (PULSAR)*
Could having more patients reach longer intervals help streamline your clinic?
*Patients completing Week 156: 8Q12/8Q16 n=375; 2Q8→8 mg n=186.
Extend treatment intervals for eligible patients across your nAMD clinic
At Week 156, approximately one quarter of patients on EYLEA 8 mg (8Q12/8Q16) achieved a last assigned dosing interval* of Q24 (PULSAR)
eSAF, patients completing Week 156.
*Patients who were randomised to the 8Q12 or 8Q16 groups at the beginning of the PULSAR study and continued treatment with EYLEA 8 mg through the PULSAR extension study Week 156; patients misassigned are included here for completeness.
†Values may not add up to 100% due to rounding.
‡One patient had a missing value for this assessment.
§Per protocol, patients in the 2Q8→8 mg group did not have sufficient time to complete a ≥Q20 treatment interval by Week 156; values may not add up to 100% due to rounding.
2Q8, 2 mg every 8 weeks; 8Q12, 8 mg every 12 weeks; 8Q16, 8 mg every 16 weeks; AE, adverse event; APTC, Anti-Platelet Trialists’ Collaboration; BCVA, best-corrected visual acuity; CRT, central retinal thickness; DMO, diabetic macular oedema; DRM, dose regimen modification; E-DRM, extension phase dose regimen modification; eFAS, extension phase full analysis set; eSAF, extension phase safety analysis set; ETDRS, Early Treatment of Diabetic Retinopathy Study; FAS, full analysis set; IOI, intraocular inflammation; IOP, intraocular pressure; IRF, intraretinal fluid; LOCF, last observation carried forward; LS, least squares; nAMD, neovascular (wet) age-related macular degeneration; N-BL, new baseline; Q8, every 8 weeks; Q16, every 16 weeks; Q20, every 20 weeks; Q24, every 24 weeks; SAE, serious adverse event; SD, standard deviation; SmPC, Summary of Product Characteristics; SRF, subretinal fluid; T&E, treat and extend; TEAE, treatment-emergent adverse event; VEGF, vascular endothelial growth factor.
PP-EYL-GB-3107 | March 2026